Using eye imaging and blood tests to detect Alzheimer's early

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on identifying specific plasma biomarkers and ocular indicators that can aid in the early detection of Alzheimer's disease. Participants aged 50 and older, including those diagnosed with Alzheimer's, mild cognitive decline, subjective cognitive decline, or who are cognitively normal, will undergo multimodal ophthalmic imaging and blood sampling. The study aims to establish a correlation between ocular changes and plasma biomarkers associated with Alzheimer's, potentially leading to earlier diagnosis and intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participants aged ≥ 50 years;
* Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
* Signed informed consent form

Exclusion Criteria:

* Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
* Inability to cooperate with cognitive assessments;
* Refusal to undergo blood sampling.

Where it's running

• Peking University First Hospital
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cervical lymphatic bypass for treating Alzheimer's disease

  This study is testing a new surgery to see if it can help people with mild to moderate Alzheimer's disease by improving the way the brain clears out harmful proteins.

  Recruiting Changi General Hospital · Singapore · NCT06965062

• Screening for financial hardship in Alzheimer's and dementia patients

  This study is trying to understand the financial struggles faced by people with Alzheimer's and their caregivers to see how it affects their well-being and care choices.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT06922188

• Brain PET imaging with [18F]Fluorbetazine to see amyloid plaques in people with normal thinking, MCI, or Alzheimer’s

  This study tests a PET scan using [18F]Fluorbetazine to see if it can reliably detect amyloid plaques in the brain across people with normal cognition, MCI, or Alzheimer's disease.

  Recruiting Phase 3 HTA Co., Ltd. · Beijing, Beijing Municipality · NCT07764679

• Treatments for sustained improvement in symptomatic Alzheimer’s disease (18 months)

  This trial tests whether adding atomoxetine or metformin to standard care helps people with Alzheimer’s disease or related dementia see lasting improvements over 18 months.

  Recruiting at 2 sites Phase 3 University College, London · Cambridge and 1 other locations · NCT07724132

• Multitasking strategy training to boost executive control in healthy older adults

  This trial tests whether a web-based multitasking game, with or without strategy training, helps healthy adults aged 60–75 improve their executive control.

  Recruiting Rutgers, The State University of New Jersey · Newark, New Jersey · NCT06995638

• Longitudinal study on cognitive health and Alzheimer's disease

  This study is testing how changes in certain brain markers relate to memory and thinking skills in people over 65 to better understand Alzheimer's disease.

  Recruiting Imperial College London · London · NCT06953167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.